Company Overview and News
THE construction sector, which has been volatile over the last few weeks, has now calmed down after the government announced that it is proceeding with the light rail transit 3 (LRT3) project and the Klang Valley Mass Rapid Transit (MRT2), but at a reduced cost.
Malaysian Resources Corp Bhd (Oct 18, 77.5 sen) Maintain buy with a lower target price (TP) of RM1.07: We take note of the approval granted by the government to continue with the light rail transit Line 3 (LRT3) project according to the announcement made on Bursa Malaysia on Wednesday. As outlined in July this year, the project will proceed until completion at a cost of RM16.6 billion. This was following the cost-reduction exercise as instructed by the new federal administration.
3204 BSMAF 1818
KUALA LUMPUR: The Light Rail Transit Line 3 (LRT3) project has received the Government’s greenlight to continue at a total project cost of RM16.6bil, according to separate filings by Malaysian Resources Corp Bhd (MRCB) and George Kent (M) Bhd after the market closed on Wednesday.
3204 BSMAF 1818
KUALA LUMPUR (Oct 17): MRCB George Kent Sdn Bhd said today the government has agreed to continue with the Light Rail Transit Line 3 (LRT3) project at a cost of RM16.6 billion – almost half or 47% of the earlier cost of RM31.45 billion in July.
3204 BSMAF 1818
KUALA LUMPUR (Oct 17): Based on corporate announcements and news flow today, stocks in focus on Thursday (Oct 18) may include Dagang Nexchange Bhd, Kumpulan Perangsang Selangor Bhd, Malaysian Resources Corp Bhd (MRCB), George Kent (M) Bhd, Gas Malaysia Bhd, Top Glove Corp Bhd, WCT Holdings Bhd and Press Metal Aluminium Holdings Bhd.
TGLVY 5843 3204 4456 5209 8869 7113 TPGVF 9679
Construction sector Maintain neutral: The outlook for the construction sector remains challenging as the federal government is reviewing ongoing infrastructure projects to reduce costs by 20%-33%. Projects that could be affected include the Klang Valley mass rapid transit Line 2 (MRT2) and light rail transit Line 3 (LRT3), Pan Borneo Highway (PBH) and Gemas-Johor Baru Electrified Double Tracking (EDT).
2852 9261 3204 5226 6238 5924 5263 5054 9679 5085 7078
George Kent (Malaysia) Bhd (Sept 28, 1.31) Downgrade to market perform with a lower target price of RM1.35: We leave a briefing feeling less excited with George Kent (Malaysia) Bhd’s near-term prospects as the project cost review on light rail transit 3 (LRT3) took longer than expected, which hindered the group from proceeding with construction work despite not being shelved by the government.
KUALA LUMPUR: George Kent (Malaysia) Bhd’s net profit dipped slightly by 3.1% to RM24.58 million for the second financial quarter ended July 31, 2018 (2QFY19), from RM25.38 million a year ago, mainly attributed to lower profit contributed by the metering division.
3204 BSMAF 1818
George Kent chairman Tan Sri Tan Kay Hock(pic) said the group’s engineering and metering divisions have continued to perform amidst challenges in the operating environment.
KUALA LUMPUR (Sept 26): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 27) may include: George Kent (Malaysia) Bhd, Axiata Group Bhd, Astro Malaysia Holdings Bhd, Bumi Armada Bhd, United Malacca Bhd, Poh Huat Resources Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Apex Equity Holdings Bhd, Poh Kong Holdings Bhd, Hai-O Enterprise Bhd and Eversendai Corp Bhd
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF
KUALA LUMPUR (Sept 26): George Kent (Malaysia) Bhd's net profit dipped slightly by 3.1% to RM24.58 million in the second financial quarter ended July 31, 2018 (2QFY19) from RM25.38 million a year ago, mainly attributed to lower profits contributed by the metering division.
3204 BSMAF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...